Skip to main content
SpringerLink
Log in

Schizophrenia drug gets negative results for negative symptoms

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Roche's bitopertin failed to improve the negative symptoms of schizophrenia in two pivotal trials, raising questions about the therapeutic potential of glycinergic neuromodulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Targeting neuromodulation by glycine.
Authors
  1. Katie Kingwell
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kingwell, K. Schizophrenia drug gets negative results for negative symptoms. Nat Rev Drug Discov 13, 244–245 (2014). https://doi.org/10.1038/nrd4294

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4294

  • Springer Nature Limited

This article is cited by

Search

Navigation